Janina Baranowska-Kortylewicz
Overview
Explore the profile of Janina Baranowska-Kortylewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ransdell-Green E, Baranowska-Kortylewicz J, Wang D
Antioxidants (Basel)
. 2025 Jan;
14(1).
PMID: 39857413
Hydroxyl radicals (OH), the most potent oxidants among reactive oxygen species (ROS), are a major contributor to oxidative damage of biomacromolecules, including DNA, lipids, and proteins. The overproduction of OH...
2.
Malik J, Podany A, Khan P, Shaffer C, Siddiqui J, Baranowska-Kortylewicz J, et al.
Cancer Med
. 2023 Nov;
12(23):21075-21096.
PMID: 37997517
Background: Pediatric brain tumors (PBT) stand as the leading cause of cancer-related deaths in children. Chemoradiation protocols have improved survival rates, even for non-resectable tumors. Nonetheless, radiation therapy carries the...
3.
Graff B, Palanivel C, Jenkins C, Baranowska-Kortylewicz J, Yan Y
Cell Death Discov
. 2023 May;
9(1):162.
PMID: 37179350
Metastatic breast cancer (mBC) is responsible for >90% of breast cancer-related deaths. Microtubule-targeting agents (MTAs) are the front-line treatment for mBC. However, the effectiveness of MTAs is frequently limited by...
4.
Baranowska-Kortylewicz J, Kortylewicz Z, McIntyre E, Sharp J, Coulter D
J Pediatr Hematol Oncol
. 2021 Sep;
44(6):293-304.
PMID: 34486544
The physiological functions of butyrylcholinesterase (BChE) and its role in malignancy remain unexplained. Our studies in children newly diagnosed with neuroblastoma indicated that BChE expressions is proportional to MYCN amplification...
5.
Kortylewicz Z, Coulter D, Han G, Baranowska-Kortylewicz J
J Labelled Comp Radiopharm
. 2020 Mar;
PMID: 32150284
Neuroblastoma, the most common extracranial solid tumor in children, accounts for nearly 8% of childhood cancers in the United States. It is a disease with pronounced clinical and biological heterogeneities....
6.
Baranowska-Kortylewicz J, Sharp J, McGuire T, Joshi S, Coulter D
Cancer Biother Radiopharm
. 2020 Feb;
35(6):418-424.
PMID: 32073902
Osteosarcoma (OST) is the most common bone tumor in children and adolescents with a second peak of incidence in elderly adults usually diagnosed as secondary tumors in Paget's disease or...
7.
Kortylewicz Z, Coulter D, Baranowska-Kortylewicz J
Cancer Biother Radiopharm
. 2019 Nov;
35(1):16-25.
PMID: 31687840
Resistance of cancer to chemo- and radiotherapy remains a major clinical problem. This study contributes to the ongoing search for agents that can bypass this resistance by developing a novel...
8.
Kortylewicz Z, Coulter D, Baranowska-Kortylewicz J
Drug Dev Res
. 2019 Oct;
81(1):62-69.
PMID: 31593323
The role of theranostics in cancer management is growing so is the selection of vectors used to deliver these modalities to cancer cells. We describe biological evaluation of a novel...
9.
Kortylewicz Z, Coulter D, Han G, Baranowska-Kortylewicz J
J Med Chem
. 2019 Jul;
63(5):2051-2073.
PMID: 31268317
High risk neuroblastoma often recurs, even with aggressive treatments. Clinical evidence suggests that proliferative activities are predictive of poor outcomes. This report describes syntheses, characterization, and biological properties of theranostic...
10.
Kortylewicz Z, Baranowska-Kortylewicz J
J Labelled Comp Radiopharm
. 2018 May;
PMID: 29707803
Microtubules are a target for a broad spectrum of drugs used as chemotherapeutics to treat hematological malignancies and solid tumors. Most of these drugs have significant dose-limiting toxicities including peripheral...